Schirmbeck R, Zerrahn J, Kuhröber A, Deppert W, Reimann J
Institut für Mikrobiologie, Universität Ulm, FRG.
Eur J Immunol. 1993 Jul;23(7):1528-34. doi: 10.1002/eji.1830230720.
Immunization of C57BL/6 (B6) mice (H-2b) with the "large tumor antigen" (T-Ag) of simian virus 40 (SV40) in its soluble form without adjuvants primed CD8+ cytotoxic T lymphocytes (CTL) in vivo. CD8+ CTL primed in vivo by this non-structural 708-amino acid (aa) viral protein, and specifically restimulated in vitro, lysed H-2b target cells, either transfected with an SV40 T-Ag-encoding vector, or transformed by SV40 infection. H-2b RMA-S transfectants expressing the complete 708 aa T-Ag (which fail to transport peptides through the endoplasmic reticulum membranes) were not lysed. CTL were also efficiently primed in vivo by injection of the N-terminal 272 aa fragment of the T-Ag. Hence, this fragment contains the structure(s) required for a soluble protein to enter the "endogenous" class I-restricted antigen processing and presentation pathway for CD8+ CTL activation. In soluble form, the complete T-Ag or the N-terminal T-Ag fragment sensitized in vitro RBL5 cells for lysis by T-Ag-specific CTL lines and clones. This in vitro sensitization was blocked by brefeldin A. In contrast, specific recognition of RBL5 cells pulsed in vitro with synthetic, immunogenic nonapeptides (derived from N-terminal T-Ag epitopes) by CTL lines was insensitive to brefeldin A. Hence, T-Ag and its 272-aa N-terminal fragment can enter the "endogenous" processing pathway and prime CD8+ CTL in vivo and in vitro.
用猿猴病毒40(SV40)的“大肿瘤抗原”(T-Ag)的可溶形式在无佐剂的情况下免疫C57BL/6(B6)小鼠(H-2b),可在体内引发CD8+细胞毒性T淋巴细胞(CTL)。由这种708个氨基酸(aa)的非结构病毒蛋白在体内引发的CD8+CTL,经体外特异性再刺激后,可裂解用编码SV40 T-Ag的载体转染或经SV40感染转化的H-2b靶细胞。表达完整708个aa T-Ag(无法通过内质网膜转运肽)的H-2b RMA-S转染细胞未被裂解。通过注射T-Ag的N端272个aa片段也可在体内有效地引发CTL。因此,该片段包含可溶性蛋白进入“内源性”I类限制性抗原加工和呈递途径以激活CD8+CTL所需的结构。以可溶形式,完整的T-Ag或N端T-Ag片段可在体外使RBL5细胞对T-Ag特异性CTL系和克隆的裂解敏感。这种体外致敏作用被布雷菲德菌素A阻断。相反,CTL系对体外脉冲用合成免疫原性九肽(源自N端T-Ag表位)的RBL5细胞的特异性识别对布雷菲德菌素A不敏感。因此,T-Ag及其272个aa的N端片段可进入“内源性”加工途径,并在体内和体外引发CD8+CTL。